Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)

Roni Bitterman, Fidi Koppel, Cristina Mussini, Yuval Geffen, Michal Chowers, Galia Rahav, Lior Nesher, Ronen Ben-Ami, Adi Turjeman, Maayan Huberman Samuel, Matthew P Cheng, Todd C Lee, Leonard Leibovici, Dafna Yahav, Mical Paul, Roni Bitterman, Fidi Koppel, Cristina Mussini, Yuval Geffen, Michal Chowers, Galia Rahav, Lior Nesher, Ronen Ben-Ami, Adi Turjeman, Maayan Huberman Samuel, Matthew P Cheng, Todd C Lee, Leonard Leibovici, Dafna Yahav, Mical Paul

Abstract

Introduction: The optimal treatment for extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae bloodstream infections has yet to be defined. Retrospective studies have shown conflicting results, with most data suggesting the non-inferiority of beta-lactam-beta-lactamase inhibitor combinations compared with carbapenems. However, the recently published MERINO trial failed to demonstrate the non-inferiority of piperacillin-tazobactam to meropenem. The potential implications of the MERINO trial are profound, as widespread adoption of carbapenem treatment will have detrimental effects on antimicrobial stewardship in areas endemic for ESBL and carbapenem-resistant bacteria. Therefore, we believe that it is justified to re-examine the comparison in a second randomised controlled trial prior to changing clinical practice.

Methods and analysis: PeterPen is a multicentre, investigator-initiated, open-label, randomised controlled non-inferiority trial, comparing piperacillin-tazobactam with meropenem for third-generation cephalosporin-resistant Escherichia coli and Klebsiella bloodstream infections. The study is currently being conducted in six centres in Israel and one in Canada with other centres from Israel, Italy and Canada expected to join. The two primary outcomes are all-cause mortality at day 30 from enrolment and treatment failure at day seven (death, fever above 38°C in the last 48 hours, continuous symptoms, increasing Sequential Organ Failure Assessment Score or persistent blood cultures with the index pathogen). A sample size of 1084 patients was calculated for the mortality endpoint assuming a 12.5% mortality rate in the control group with a 5% non-inferiority margin and assuming 100% follow-up for this outcome.

Ethics and dissemination: The study is approved by local and national ethics committees as required. Results will be published, and trial data will be made available.

Trial registration numbers: ClinicalTrials.gov Registry (NCT03671967); Israeli Ministry of Health Trials Registry (MOH_2018-12-25_004857).

Keywords: epidemiology; infection control; microbiology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Elnasasra A, Alnsasra H, Smolyakov R, et al. . Ethnic diversity and increasing resistance patterns of hospitalized community-acquired urinary tract infections in southern Israel: a prospective study. Isr Med Assoc J 2017;19:538-542.
    1. CDC Antibiotic resistance threats in the United States, 2013. Current 2013;114
    1. Scheuerman O, Schechner V, Carmeli Y, et al. . Comparison of predictors and mortality between bloodstream infections caused by ESBL-producing Escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2018;39:660–7. 10.1017/ice.2018.63
    1. Paul M, Shani V, Muchtar E, et al. . Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54:4851–63. 10.1128/AAC.00627-10
    1. Tam VH, Ledesma KR, Chang K-T, et al. . Killing of Escherichia coli by β-lactams at different inocula. Diagn Microbiol Infect Dis 2009;64:166–71. 10.1016/j.diagmicrobio.2009.01.018
    1. Paterson DL, Ko W-C, Von Gottberg A, et al. . Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31–7. 10.1086/420816
    1. Rodríguez-Baño J, Navarro MD, Retamar P, et al. . β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167–74. 10.1093/cid/cir790
    1. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, et al. . A multinational, Preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2016;60:4159–69. 10.1128/AAC.00365-16
    1. Tamma PD, Han JH, Rock C, et al. . Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 2015;60:1319–25. 10.1093/cid/civ003
    1. Muhammed M, Flokas ME, Detsis M, et al. . Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis. Open Forum Infect Dis 2017;4:ofx099. 10.1093/ofid/ofx099
    1. Harris PNA, Tambyah PA, Lye DC, et al. . Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 2018;320:984–94. 10.1001/jama.2018.12163
    1. Erratum Missing information on sample size. JAMA 2019;321:2370. 10.1001/jama.2019.6706
    1. Button KS, Ioannidis JPA, Mokrysz C, et al. . Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013;14:365–76. 10.1038/nrn3475
    1. Bassler D, Briel M, Montori VM, et al. . Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180–7. 10.1001/jama.2010.310
    1. Montori VM, Devereaux PJ, Adhikari NKJ, et al. . Randomized trials stopped early for benefit: a systematic review. JAMA 2005;294:2203–9. 10.1001/jama.294.17.2203
    1. Murad MH, Guyatt GH, Domecq JP, et al. . Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit. J Clin Epidemiol 2017;82:12–19. 10.1016/j.jclinepi.2016.10.006
    1. Problems with piperacillin-tazobactam gradient tests from two manufacturers Eucast warnings concerning antimicrobial susceptibility testing products or procedures. Available:
    1. Henderson A, Tambyah P, Lye D. Association with 30-day mortality and MIC in patients treated with piperacillin/tazobactam for Escherichia coli and Klebsiella pneumoniae bloodstream infections that are non-susceptible to ceftriaxone from patients enrolled in the MERINO trial In: 29Th ECCMID, 2019.
    1. Harris PNA, Tambyah P, Paterson DL. Antibiotics for ceftriaxone resistant gram-negative bacterial bloodstream Infections-Reply. JAMA 2019;321:613–4. 10.1001/jama.2018.19353
    1. Livermore DM, Day M, Cleary P, et al. . OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli. J Antimicrob Chemother 2019;74:326–33. 10.1093/jac/dky453
    1. Felton TW, Hope WW, Lomaestro BM, et al. . Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother 2012;56:4087–94. 10.1128/AAC.00521-12
    1. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Kahlmeter G. Antibiotics for ceftriaxone-resistant gram-negative bacterial bloodstream infections. JAMA 2019;321:612–3. 10.1001/jama.2018.19345
    1. WHO Antibacterial agents in clinical development.
    1. The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. version 9.0. 2019. Available: [Accessed 19 Feb 2019].
    1. CLSI Clinical and laboratory Standards Institute. performance standards for antimicrobial susceptibility testing. 2018, 2018. Available: [Accessed 8 Mar 2018].
    1. Harris PA, Taylor R, Minor BL, et al. . The REDCap Consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208. 10.1016/j.jbi.2019.103208
    1. Mo Y, Lim C, Watson JA, et al. . Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ 2020;370:m2215. 10.1136/bmj.m2215
    1. Andersen MG, Thorsted A, Storgaard M, et al. . Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered? Antimicrob Agents Chemother 2018;62. 10.1128/AAC.02306-17. [Epub ahead of print: 26 04 2018].
    1. Roberts JA, Ulldemolins M, Roberts MS, et al. . Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010;36:332–9. 10.1016/j.ijantimicag.2010.06.008
    1. Chung EK, Cheatham SC, Fleming MR, et al. . Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. J Clin Pharmacol 2015;55:899–908. 10.1002/jcph.505
    1. Udy AA, Lipman J, Jarrett P, et al. . Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 2015;19:28. 10.1186/s13054-015-0750-y
    1. Sime FB, Hahn U, Warner MS, et al. . Using population pharmacokinetic modeling and Monte Carlo simulations to determine whether standard doses of piperacillin in piperacillin-tazobactam regimens are adequate for the management of febrile neutropenia. Antimicrob Agents Chemother 2017;61. 10.1128/AAC.00311-17. [Epub ahead of print: 24 10 2017].
    1. Vardakas KZ, Voulgaris GL, Maliaros A, et al. . Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 2018;18:108–20. 10.1016/S1473-3099(17)30615-1
    1. Li L, Li X, Xia Y. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Front Pharmacol 2020;11.
    1. Mouton JW, Muller AE, Canton R, et al. . MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 2018;73:564–8. 10.1093/jac/dkx427
    1. Isla A, Canut A, Arribas J, et al. . Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis 2016;35:511–9. 10.1007/s10096-015-2568-6
    1. Vincent JL, Moreno R, Takala J, et al. . The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. on behalf of the Working group on sepsis-related problems of the European Society of intensive care medicine. Intensive Care Med 1996;22:707–10. 10.1007/BF01709751
    1. Harris PNA, McNamara JF, Lye DC, et al. . Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clin Microbiol Infect 2017;23:533–41. 10.1016/j.cmi.2016.10.023
    1. Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, et al. . Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2017;35:dkw513 10.1093/jac/dkw513
    1. Sealed Envelope Ltd Power calculator for binary outcome non-inferiority trial, 2012
    1. Yahav D, Franceschini E, Koppel F, et al. . Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a Noninferiority randomized controlled trial. Clin Infect Dis 2019;69:1091–8. 10.1093/cid/ciy1054
    1. Cheng MP, Lawandi A, Butler-Laporte G, et al. . Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized controlled trial. Clin Infect Dis 2020. 10.1093/cid/ciaa1000. [Epub ahead of print: 15 Jul 2020].
    1. Peto R, Pike MC, Armitage P, et al. . Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977;35:1–39. 10.1038/bjc.1977.1
    1. Haybittle JL Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793–7. 10.1259/0007-1285-44-526-793
    1. Bellomo R, Kellum JA, Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the rifle criteria. Intensive Care Med 2007;33:409–13. 10.1007/s00134-006-0478-x

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren